Rationale for IL-37 as a novel therapeutic agent in inflammation

References

• Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010 Nov;11(11):1014–1022.
   PubMed Web of Science ®Google Scholar
• Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. PNAS. 2014 Oct 21;111(42):15178–15183.
   PubMed Web of Science ®Google Scholar
• Ellisdon AM, Nold-Petry CA, D’Andrea L, et al. Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Sci Immunol. 2017 Feb 10;2(8). DOI:10.1126/sciimmunol.aaj1548.
   PubMed Web of Science ®Google Scholar
• Rudloff I, Cho SX, Lao JC, et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells. J Leukoc Biol. 2017 Apr;101(4):901–911.
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015 Apr;16(4):354–365.
   PubMed Web of Science ®Google Scholar
• Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014 Sep 3;5(1):4711.
   PubMedGoogle Scholar
• Rudloff I, Ung HK, Dowling JK, et al. Parsing the IL-37-mediated suppression of inflammasome function. Cells. 2020 Jan 10;9(1):178.
   Web of Science ®Google Scholar
• McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. PNAS. 2011 Oct 4;108(40):16711–16716.
   PubMed Web of Science ®Google Scholar
• Lunding L, Webering S, Vock C, et al. IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015 Apr;70(4):366–373.
   PubMed Web of Science ®Google Scholar
• Bulau AM, Fink M, Maucksch C, et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal. 2011;11:2480–2490.
   PubMed Web of Science ®Google Scholar
• Eisenmesser EZ, Gottschlich A, Redzic JS, et al. Interleukin-37 monomer is the active form for reducing innate immunity. PNAS. 2019 Mar 19;116(12):5514–5522.
   PubMed Web of Science ®Google Scholar
• Bujotzek A, Tiefenthaler G, Lariviere L, et al. Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential. Cell Chem Biol. 2021 Oct 19;29(4):586–596.e4.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016 Dec;55(12):2220–2229.
   PubMed Web of Science ®Google Scholar
• Cao S, Shi H, Sun G, et al. Serum IL-37 level is associated with rheumatoid arthritis and disease activity: a meta-analysis. Biomed Res Int. 2021;2021:6653439.
   PubMed Web of Science ®Google Scholar
• Ye L, Ji L, Wen Z, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med. 2014 Mar 16;12(1):69.
   PubMedGoogle Scholar
• Godsell J, Rudloff I, Kandane-Rathnayake R, et al. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep. 2016 Oct 6;6(1):34604.
   PubMedGoogle Scholar
• Cho SX, Rudloff I, Lao JC, et al. Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities. Nat Commun. 2020 Nov 13;11(1):5794.
   PubMed Web of Science ®Google Scholar
• Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 2013 Jun;172(3):410–416.
   PubMed Web of Science ®Google Scholar
• Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines. Cytokine. 2015 Dec;76(2):553–557.
   PubMed Web of Science ®Google Scholar
• Kluck V, van Deuren RC, Cavalli G, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis. 2020 Apr;79(4):536–544.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen J, Li W, et al. Additive therapeutic effects of mesenchymal stem cells and IL-37 for systemic lupus erythematosus. J Am Soc Nephrol. 2020 Jan;31(1):54–65.
   PubMed Web of Science ®Google Scholar
• Tawfik MG, Nasef SI, Omar HH, et al. Serum Interleukin-37: a new player in Lupus Nephritis? Int J Rheum Dis. 2017 Aug;20(8):996–1001.
   PubMed Web of Science ®Google Scholar
• Li A, Ling Y, Song Z, et al. Correlation between early plasma interleukin 37 responses with low inflammatory cytokine levels and benign clinical outcomes in severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021 Feb 24;223(4):568–580.
   PubMed Web of Science ®Google Scholar
• Christie MJ, Irving AT, Forster SC, et al. Of bats and men: immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci Immunol. 2021 Sep 17;6(63):eabd0205.
   PubMed Web of Science ®Google Scholar
• Schroder A, Lunding LP, Zissler UM, et al. IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33. Allergy. 2022 Mar;77(3):856–869.
   PubMed Web of Science ®Google Scholar
• Zhang SR, Nold MF, Tang SC, et al. IL-37 increases in patients after ischemic stroke and protects from inflammatory brain injury, motor impairment and lung infection in mice. Sci Rep. 2019 May 6;9(1):6922.
   PubMedGoogle Scholar
• Wu B, Meng K, Ji Q, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014 Jun;176(3):438–451.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang ZX, Lian D, et al. IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int. 2015 Feb;87(2):396–408.
   PubMed Web of Science ®Google Scholar
• Ji Q, Meng K, Yu K, et al. Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice. Sci Rep. 2017 Jun 12;7(1):3310.
   PubMedGoogle Scholar
• Cavalli G, Justice JN, and Boyle KE, et al. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. PNAS. 2017 Feb 28;114(9):2313–2318.
   PubMed Web of Science ®Google Scholar
• Ballak DB, Li S, Cavalli G, et al. Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. J Biol Chem. 2018 Sep 14;293(37):14224–14236.
   PubMed Web of Science ®Google Scholar